Literature DB >> 20180098

Characterisation of the prostanoid receptor mediating inhibition of smooth muscle contractility in the rat prostate gland.

Slavko Tokanovic1, Carl W White, Daniel T Malone, Betty Exintaris, Sabatino Ventura.   

Abstract

This study characterised the inhibitory actions of prostaglandins on smooth muscle contractility in the rat prostate gland. Immunohistochemical studies were carried out to identify and localise the two isoforms of cyclooxygenase (COX) enzyme and the subtypes of prostanoid receptors present in the rat prostate. Isolated organ bath studies were carried out to pharmacologically characterise the subtype of prostanoid receptor mediating the inhibitory effects of prostanoids on the rat prostate. Immunohistochemical studies confirmed the presence of mainly COX-2 within the prostatic stroma. Isolated organ bath studies showed that prostaglandin E(2) (PGE(2); 10 nM-10 microM) but not prostaglandin D(2) (10 nM-10 microM), PGF2alpha (10 nM-10 microM), prostacyclin (10 nM-10 microM) or U46619 (10 nM-10 microM) inhibited nerve-mediated contractile responses to electrical field stimulation. Similarly, sulprostone (10 nM-10 microM) had no affect on the magnitude of the electrically evoked contractions. PGE(2) (0.1-10 microM) did not affect contractions elicited by noradrenaline or adenosine 5'-triphosphate. PGE(2)-mediated inhibition of electrical field stimulation induced contractions was attenuated by AH 6809 (10 microM) but not SC 19220 (10 microM) or AH 23848 (10 microM). It is concluded that prostaglandins can inhibit contractions of the rat prostate gland through a prostanoid receptor of the EP(2) subtype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180098     DOI: 10.1007/s00210-010-0492-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  Guide to Receptors and Channels (GRAC), 2nd edition (2007 Revision).

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2007-02       Impact factor: 8.739

2.  Responsiveness of smooth muscle in the lower urinary tract of rabbits to various agonists.

Authors:  K Sudoh; O Inagaki; K Honda
Journal:  Gen Pharmacol       Date:  1997-04

Review 3.  Prostanoid receptors: structures, properties, and functions.

Authors:  S Narumiya; Y Sugimoto; F Ushikubi
Journal:  Physiol Rev       Date:  1999-10       Impact factor: 37.312

Review 4.  International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.

Authors:  R A Coleman; W L Smith; S Narumiya
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

Review 5.  Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

Authors:  Gero Kramer; Dieter Mitteregger; Michael Marberger
Journal:  Eur Urol       Date:  2006-12-11       Impact factor: 20.096

6.  Adenosine 5'-triphosphate (ATP) is an excitatory cotransmitter with noradrenaline to the smooth muscle of the rat prostate gland.

Authors:  Sabatino Ventura; Ramila K Dewalagama; Linda C L Lau
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

7.  Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland.

Authors:  S Tokanovic; D T Malone; S Ventura
Journal:  Br J Pharmacol       Date:  2006-11-13       Impact factor: 8.739

8.  Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate.

Authors:  Alaa F Badawi; Yingying Liu; Mazen B Eldeen; Willard Morrow; Zaineb R Razak; Marie Maradeo; Mostafa Z Badr
Journal:  Carcinogenesis       Date:  2004-04-29       Impact factor: 4.944

Review 9.  Prostate growth and inflammation.

Authors:  Alessandro Sciarra; Gianna Mariotti; Stefano Salciccia; Ana Autran Gomez; Salvatore Monti; Vincenzo Toscano; Franco Di Silverio
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-07       Impact factor: 4.292

10.  Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue.

Authors:  S Kitada; J Kumazawa
Journal:  J Urol       Date:  1987-07       Impact factor: 7.450

View more
  4 in total

1.  Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: roles of PGE₂ and EP receptors.

Authors:  You-Min Lin; Sushil K Sarna; Xuan-Zheng Shi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

Review 2.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

3.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

4.  Prostaglandin E2 and F2alpha Modulate Urinary Bladder Urothelium, Lamina Propria and Detrusor Contractility via the FP Receptor.

Authors:  Zane Stromberga; Russ Chess-Williams; Christian Moro
Journal:  Front Physiol       Date:  2020-06-23       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.